David Hoos

David Hoos

David Hoos

Associate Research Scientist


722 West 168th Street
New York 10032


David Hoos, MD, MPH, is a board certified internist, and Project Director of ICAP's PHIA Project, which is conducting population-based HIV impact assessments to measure HIV incidence and viral suppression in 15 PEPFAR-supported countries. He was Senior Implementation Director at ICAP from 2004 to 2013 and was the Director of the Multicountry Columbia Antiretroviral Program (MCAP), an eight-year cooperative agreement funded by the CDC, which supported the scale-up of HIV prevention, care and treatment in eight sub-Saharan African countries. Dr. Hoos was an initial member of the MTCT Plus Secretariat at Columbia's Mailman School of Public Health and was responsible for establishing the procurement system for antiretroviral and other HIV-associated medications and diagnostics for the program sites. Dr. Hoos has been recognized as a technical expert in a number of areas related to HIV policy and programming. He served as a member of the Technical Review Panel for the Global Fund for AIDS, TB and Malaria (GFATM), as well as a co-chair for the Procurement and Supply Management Advisory Panel to the GFATM on procurement-related policy and country guidance. He has been a member of several WHO technical panels. Dr. Hoos earned his medical degree from New York Medical College and holds a Master of Public Health degree.



MPH, 1992, Mailman School of Public Health Columbia University
MD, 1981, New York Medical College
BA, 1975, University of Wisconsin

Areas of Expertise

Global Health, HIV/AIDS

Select Global Activities

Columbia Multicountry Antiretroviral Program: Dr. Hoos is the Senior Implementation Director at the International Center for AIDS Care and Treatment Programs, and program director for MCAP, the Multicountry Columbia Antiretroviral Program, a CDC funded program to support the provision of HIV prevention, care and treatment services in 8 countries in Africa. Dr. Hoos has also served in a number of capacities for Global Fund panels.

Back to Top